Anti-apoptotic members of the Bcl-2 family, such as Bcl-w, maintain cell viability by preventing the activation of the cell death effectors, the caspases. Gene targeting experiments in mice have demonstrated that Bcl-w is required for spermatogenesis and for survival of damaged epithelial cells in the gut. Bcl-w is, however, dispensable for physiological cell death in other tissues. Here we report on the analysis of Bcl-w protein expression using a panel of novel monoclonal antibodies. Bclw is found in a diverse range of tissues including colon, brain and testes. A survey of transformed cell lines and purified hematopoietic cells demonstrated that Bcl-w is expressed in cells of myeloid, lymphoid and epithelial origin. Subcellular fractionation and confocal laser scanning microscopy demonstrated that Bcl-w protein is associated with intracellular membranes. The implications of these results are discussed in the context of the phenotype of Bcl-w-null mice and recent data that suggest that Bcl-w may play a role in colon carcinogenesis. Cell Death and Differentiation (2001) 8, 486 ± 494.
Introduction
Apoptotic cell death plays a critical role in moulding embryonic tissues, in regulating cell turnover and in defending the host against pathogens. 1, 2 Failure of cells to undergo appropriate apoptosis can lead to cellular transformation 3 or autoimmunity, 4, 5 whereas premature apoptosis of long-lived cells has been implicated in the pathology of degenerative disorders. 6 Cell death can be induced under a variety of physiological and experimentally induced conditions. These cytotoxic stimuli can activate distinct signaling pathways that converge upon a common cell death effector machinery driven by cysteine proteases (caspases). Certain caspases (`initiator caspases') are activated through autocatalytic processing, with the help of adapter proteins, while others (`effector caspases') are activated by already active caspases. 7, 8 Members of the Bcl-2 protein family are key regulators of cell death. 9 Mammalian Bcl-2 and its closest relatives, such as Bcl-x L and Bcl-w, are thought to prevent caspase activation by inhibiting adapter proteins, either by direct interaction or by blocking release of apoptogenic co-factors from mitochondria. 8, 10 The pro-survival function of the Bcl-2-like anti-apoptotic sub-family can be inhibited by the relatively closely related Bax sub-family, and also by distant relatives, such as Bik (Nbk) and Bim (Bod), which share only the short BH3 domain. 9 The pro-apoptotic proteins bind to Bcl-2 or its functional homologs via their BH3 domain 11 and it is believed this initiates the cell death effector machinery. 8, 9 Bcl-w was originally cloned by virtue of its sequence homology to other Bcl-2 family members. 12 As with Bcl-2 and Bcl-x L , Bcl-w overexpression renders cells refractory to cell death induced by many death stimuli, but not that triggered by members of the TNF-R family that have à death domain' (e.g. TNF-R1 or Fas). 12, 13 Gene targeting experiments in mice have revealed that Bcl-w is essential for spermatogenesis ± mutant males were sterile due to a gradual depletion of all stages of germ cells. 14, 15 Bcl-w appeared to be dispensable for normal development and functioning of all other organs, presumably because these also expressed other pro-survival Bcl-2 family members.
Northern blot analysis had shown that bcl-w mRNA is expressed in diverse tissues and in many myeloid cell lines. 12 To investigate the expression of Bcl-w protein, we have now generated specific monoclonal antibodies (mAb). Bcl-w was found to be widely expressed in normal mouse tissues, particularly in the brain, spinal cord, colon, testes, most hematopoietic cells and fibroblasts. Bcl-w was also found in a variety of transformed murine and human cell lines of epithelial origin. Subcellular fractionation and confocal laser scanning microscopy revealed Bcl-w on cytoplasmic membranes, such as the nuclear envelope, outer mitochondrial membrane and possibly the endoplasmic reticulum (ER). Thus, Bcl-w has a subcellular localization comparable to that of its closest pro-survival relatives, Bcl-2 and Bcl-x L . mixture of parental FDC-P1 cells and a subline stably expressing EE-tagged Bcl-w. Antibodies specific to Bcl-w were revealed by a double immunofluorescence peak ( Figure  1C ,D) as seen also by staining with the anti-EE epitope tagspecific antibody ( Figure 1B ). The peak with lower immunofluorescence intensity represents background immunofluorescence of unstained parental FDC-P1 cells and the higher intensity peak represents specific Bcl-w staining in the stably transfected FDC-P1-EE-Bcl-w cells. Nineteen anti-Bcl-w antibody-secreting clones were expanded and subcloned from an initial screen of 2000 hybridoma cultures.
Two independent mAbs (13F9 and 16H12) that recognize both mouse and human Bcl-w and were efficacious in many applications, including immunofluorescence staining, Western blotting and immunoprecipitation ( Figure 1E ), were chosen for further experiments. Immunoblotting of lysates of 293T cells transiently transfected with expression constructs for different Bcl-2 family members demonstrated that the two mAbs recognized Bcl-w but not Bcl-2, Bcl-x L , Bak, Bax, Bad or Bim (Figure 2A ± C). Both mAbs detected the 21 kDa Bcl-w protein from tissue lysates of normal mice but not from those of Bcl-wdeficient mice ( Figure 4A ,B). Some cross-reactivity was observed on Western blotting but only to two proteins considerably larger than Bcl-w, so this did not preclude their use in expression analysis.
Expression of Bcl-w in cell lines and mouse tissues
Bcl-w expression in cell lines was determined by Western blotting of immunoprecipitates from cell lysates. Examples of such IP/Western blots are shown in Figure 3 and the overall results are summarized in Table 1 . Readily detectable levels of Bcl-w were found in cell lines of myeloid (416B, BAF-3 and FDC-P1), fibroblast (NIH3T3, Rat-1 and L929) and epithelial origin (MCF-7, SW480 and EB-3). Bcl-w protein was not detected in most lymphoid cell lines (B and T) and, where it was expressed (e.g. ABLS 8.1, CH1 and SP2/0), the levels were often low. In thymic lymphoma-derived lines Bcl-w expression was only found in cells with a CD4 7 8 7 phenotype (Table 1) , representing a very early stage of T cell development.
A broad survey of normal mouse tissues by Western blotting readily detected Bcl-w in the brain, spinal cord, colon, testes, pancreas, heart, spleen and mammary glands of pregnant mice ( Figure 4A ,B). Moderate levels of Bcl-w were also found in thymus, ovary and small intestine but no Bcl-w expression could be detected in salivary gland (not shown), muscle or liver. Sub-populations of hematopoietic cells from thymus, lymph nodes and bone marrow were isolated by immunofluorescence staining for specific surface markers followed by flow cytometry. Western blotting of cell lysates detected Bcl-w in all four major thymocyte sub-populations, mature B and T cells in lymph nodes, and in granulocytes, monocytes and erythroid cells from bone marrow ( Figure 4B ). Collectively, these results demonstrate that Bcl-w is expressed in reproductive organs and in cells of hematopoietic, fibroblastoid, neuronal and epithelial lineages.
Subcellular localization of Bcl-w
We next wished to compare the subcellular localization of Bclw with that of its closest homologs, Bcl-2 and Bcl-x L . Electron and confocal microscopy studies have previously demonstrated that Bcl-2 is located on the cytoplasmic face of the outer mitochondrial membrane, the nuclear envelope and the endoplasmic reticulum 17, 18 and Bcl-x L resides on the outer mitochondrial membrane. 19 While Bcl-2 is exclusively membrane-bound in subcellular fractionation experiments, a proportion of Bcl-x L is found in the soluble fraction in lysates prepared from healthy cells. After a death stimulus, however, both proteins are present exclusively in the insoluble pellet fraction. 20, 21 To investigate the subcellular localization of Bcl-w, we chose to mechanically disrupt cells by Dounce homogenization, rather than lysing them with non-ionic detergents which has been shown to cause artefactual changes in localization of Bcl-2 family members. 22 Subcellular fractions of healthy HeLa cells were analyzed by immunoblotting with mAbs 13F9 and 16H12 ( Figure 5 ). Most of the Bcl-w protein was associated with the heavy membrane (HM) fraction, as was most of Bcl-2 and Bcl-x L . (Under these conditions, the mitochondria and ER are likely to have fractionated in the HM fraction since their respective markers, VDAC/porin and calnexin, were found exclusively in this fraction.) However, a significant amount of Bcl-w was present in the soluble cytosolic fraction (S), which also contained some Bcl-x L but negligible amounts of Bcl-2. After UV irradiation ( Figure 5 ) or treatment with staurosporine or etoposide (data not shown), neither Bcl-w nor Bclx L was present at substantial levels in the soluble fraction. Two explanations could account for the differences in subcellular fractionation of Bcl-w and Bcl-x L between healthy cells and cells undergoing apoptosis. A proportion of Bcl-w or Bcl-x L might normally be cytosolic and only translocates to intracellular membranes upon induction of Figure 3 Bcl-w expression in cultured mouse and human cell lines. Bcl-w protein was revealed in lysates from mouse and human cell lines by Western blotting and detection by ECL Figure 4 Bcl-w expression in normal mouse tissues and in purified hematopoietic cell types. Western blot analysis of Bcl-w expression in normal mouse tissues (A) and in sorted lymphoid, myeloid and erythroid cells from bone marrow, thymus and lymph nodes (B). Tissue lysates and lysates of sorted cells were prepared, normalized for total protein content and 30 mg of protein were size-fractionated by SDS ± PAGE and electroblotted onto nitrocellulose. Immunoblot analysis with mAb 16H12 was performed as described in the legend to Figure 3 . Equal protein loading was demonstrated by immunoblotting with a mAb specific to HSP 70 apoptosis. Alternatively, these proteins might normally be only weakly attached to intracellular membranes and therefore easily stripped off during fractionation. During apoptosis induction, Bcl-w attachment to cytoplasmic membranes might be strengthened by increased association with other membrane-anchored proteins.
To explore this further, we studied Bcl-w localization by immunofluorescence staining and confocal microscopy. In view of the cross-reactivity of the antibodies to Bcl-w, HeLa cells stably expressing EE-epitope tagged Bcl-w were stained with an anti-EE mAb, which did not produce any non-specific staining, were used for these experiments. Confocal microscopic analysis of three independently derived Bcl-w-expressing HeLa cell lines showed staining around the nuclear envelope and a punctate cytoplasmic pattern (Figure 6A ± C). Mitotracker Red was used to identify mitochondria. This revealed that most (if not all) cytoplasmic Bcl-w staining is likely to be mitochondrial as there was very substantial overlap with Mitotracker Red staining ( Figure 6D ± I) . We therefore conclude that Bcl-w has a subcellular distribution comparable to its closest homologs, Bcl-2 17 and Bcl-x L . 21 
Discussion
Bcl-w like its closest relatives, Bcl-2 and Bcl-x L , protects cells against a wide range of apoptotic stimuli, although not those triggered by ligation of`death receptors'. 12 Our subcellular fractionation ( Figure 5 ) and confocal microscopy ( Figure 6 ) analyses demonstrated that Bcl-w protein is localized to the nuclear envelope and mitochondria, the same sites where Bcl-2 and Bcl-x L reside. 17 ± 19 No significant levels of Bcl-w could be detected by confocal microscopy in the cytosol of HeLa cells, even when the protein was overexpressed ( Figure 6 ). Since Bcl-w has a hydrophobic C-terminal tail like Bcl-2 and Bcl-x L , it is likely that Bcl-w is attached to cytoplasmic membranes in a manner similar to those two pro-survival molecules. However, Bcl-w association with cytoplasmic membranes appears to be easily disrupted during subcellular fractionation, since some appears in the soluble fraction ( Figure 5 ), as is the case for Bclx L 20,21 (and Figure 5) . Interestingly, in cells exposed to an apoptotic stimulus, the attachment of Bcl-w (and Bcl-x L ) to membranes appeared to be stronger. The basis for the change in Bcl-w in cells exposed to apoptotic stimuli remains to be determined but may be related to the translocation to cytoplasmic membranes of pro-apoptotic Bcl-2 family members, such as Bax, Bad or Bim. 21, 23, 24 Although Bcl-w is functionally and biochemically very similar to Bcl-2 or Bcl-x L , their primary physiologic activities differ. Gene targeting experiments in mice have demonstrated that Bcl-w plays a critical role during spermatogenesis but is not obligatory for other developmental processes. 14, 15 In contrast, Bcl-2 is critical for normal development of the kidney, lymphocyte survival and hair growth, 25 whereas Bcl-x is essential for erythropoiesis and neuronal development. 26 The more distant pro-survival relatives Mcl-1 and A1 appear to be required for preimplantation development and embryo implantation 27 and for granulocyte survival, 28 respectively. Thus, some cell types appear to rely (almost) exclusively on one Bcl-2-like protein for survival, whereas others may be protected by several family members due to overlapping expression. Earlier Northern blot analysis indicated that Bcl-w has a widespread expression pattern. 12 Using our novel anti-Bcl-w mAbs, we showed that Bcl-w is expressed in a range of tissues with high levels detected in the brain, spinal cord, testes, colon and moderate levels found in the heart, pancreas, small intestine, ovary and hematopoietic tissues (Figures 3 and 4) . As these organs appeared histologically normal in Bcl-w-deficient mice, 14 ,15 it appears likely that expression of other anti-apoptotic Bcl-2 family members is sufficient to maintain normal cell survival in these tissues.
A survey of cell lines and primary mouse hematopoietic cells revealed that Bcl-w protein is expressed in lymphocytes, macrophages, granulocytes, megakaryocytes and erythroid cells (Figures 3 and 4) . Many other pro-survival Bcl-2 family members are also expressed in hematopoietic cells and some were shown to be essential for their survival. Bcl-2 is required for IL-7R-mediated survival of T cell progenitors 29, 30 and longevity of mature lymphocytes. 25 Bcl-x L expression is induced by EPO-R-mediated Stat5a/b activation 31, 32 and is essential for survival of erythroid cells during embryogenesis. 26 A1 plays a limited role in granulocyte survival. 28 Interestingly, mice lacking the BH3-only protein Bim have excess lymphocytes, monocytes and granulocytes, 33 indicating that it is the critical activator of apoptosis in all of these cell types. In spite of the lack of any obvious hematopoietic defect in Bcl-wdeficient mice, Bcl-w may play an auxiliary role in hematopoietic cell survival under certain circumstances. Such functions might be uncovered in mutant animals lacking Bcl-w plus one or several other anti-apoptotic Bcl-2 family members.
The highest levels of Bcl-w were found in the brain of adult mice (Figure 4) . Many of the other anti-apoptotic Bcl-2 family members, including Bcl-2 and Bcl-x L , are also expressed in the brain. 26, 34 Bcl-x-deficient mice die around E15 with massive neuronal apoptosis 35 demonstrating that Bcl-x L is essential for cell survival in the developing central nervous system. It is presently unknown which Bcl-2 family member(s) is (are) required to maintain neuronal survival in adult animals. Although Bcl-w-deficient mice have no obvious abnormalities in the nervous system, 14, 15 Bcl-w might have a neuroprotective function under conditions of stress. Consistent with this idea it has been observed that Bcl-w expression is increased in ischaemic regions of the rat brain. 35 Bcl-w expression was also found in several tumor-derived cell lines of epithelial origin ( Figure 3 ) and in mouse tissues that are rich in epithelial cells (Figure 4) . Tissues of epithelial origin are therefore another cell type in which Bcl-w may play a role in inhibiting apoptosis. Neither untreated Bcl-wdeficient mice nor any of the other mutant animals lacking individual anti-apoptotic Bcl-2 family members have known abnormalities in the gastrointestinal tract. It is therefore possible that under normal physiologic circumstances, specific defects in these tissues may only be manifest in mice lacking two or several anti-apoptotic Bcl-2 family members. However, recent studies have shown that gut epithelial cells from Bcl-w-deficient mice are abnormally sensitive to g-irradiation or treatment with the cytotoxic drug 5-fluorouracil. 36 Moreover, Bcl-w levels are increased in epithelial cells adjacent to resected gut segments, 37 indicating that Bcl-w might protect against stress in this scenario. Interestingly, many human colon cancers express strikingly high levels of Bcl-w 38 ( Figure 3 and Table 1 ). Hence, Bcl-w may play a role in the pathogenesis of colonic tumors. It will therefore be interesting to investigate whether Bcl-w-deficiency affects tumor incidence or latency in mutant mouse strains that are predisposed to colon cancer, such as the min mice which lack the APC tumor suppressor.
In conclusion, our expression analyses identify a range of tissues, besides the testes, in which Bcl-w might play a role in blocking apoptosis.
Materials and Methods

Experimental animals
All experiments with animals were performed according to the guidelines of the Royal Melbourne Hospital Research Foundation Animal Ethics Committee. Wistar rats and C57BL/6 mice were obtained from our Institute's breeding facility.
Expression constructs and protein puri®cation
Epitope (EE-or HA-tagged) expression vectors for Bcl-w, Bcl-2, Bclx L , Bax, Bak, Bim and Bad have been previously described 39, 40 or were generated by subcloning into derivatives of pEF PGKpuro or pEF PGKhygro vectors, incorporating the N-terminal EE (EYMPME) 41 or HA (YPYDVPDYA) 42 epitope tags. All constructs were verified by automated sequencing (ABI Perkin Elmer). The vector pQE-9 Bcl-w was constructed by subcloning the full-length human bcl-w gene inframe with the N-terminal (His) 6 tag in pQE-9 (Qiagen). Recombinant (His) 6 -tagged Bcl-w protein was produced in SG13009 [ P REP 4] cells and purified on a nickel column according to the manufacturer's protocols (Qiagen).
Immunization, hybridoma fusion and screening for antibodies to Bcl-w Wistar rats were initially immunized by subcutaneous (s.c.) injection with 100 mg purified recombinant human Bcl-w protein dissolved in complete Freund's adjuvant (Difco). Two subsequent boosts of the immunogen, resuspended in incomplete Freund's adjuvant (Difco), were injected s.c. 3 and 6 weeks later. A final boost with Bcl-w protein dissolved in PBS was given intravenously (i.v.) and i.p. 4 weeks after this. Three days later, hybridomas were generated by fusing spleen cells from immunized rats with the SP2/0 myeloma cell line as previously described. 16, 43 Hybridomas producing monoclonal antibodies to Bcl-w were identified and their isotype determined using a screening strategy that we have previously described. 16 Briefly, parental FDC-P1 cells and a subclone stably expressing EE-tagged mouse or human Bcl-w were mixed at a 1 : 1 ratio, fixed in 1% paraformaldehyde, permeabilized with 0.3% saponin (Sigma) and stained with hybridoma supernatants. Bound antibodies were revealed with fluorescein-isothyocyanate (FITC)-conjugated goat anti-rat Ig antibodies (Southern Biotechnology) and analyzed in a FACScan analyzer (Becton Dickinson). Hybridomas producing antibodies to Bcl-w were cloned twice and adapted for growth in medium containing low serum. For production of large amounts of antibodies, hybridomas were cultured for several weeks in the miniPERM classic 12.5 kDa production and nutrient module (Heraeus). Antibodies were purified on a protein-G sepharose column (Pharmacia).
Cell lines, tissue culture and transfection with expression constructs
The cell lines used for analysis of Bcl-w expression are indicated in Table 1 . Details of these cell lines are available from the authors. The cells were cultured in the high glucose version of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 50 mM 2-mercaptoethanol (2-ME), 13 mM folic acid and 100 mM L-asparagine, or were grown in DME or RPMI medium with 10% FCS. Cultures of parental FDC-P1 and BAF-3 cells and their derivatives were supplemented with IL-3 (1000 U/ml). FDC-P1 clones stably expressing EE-tagged mouse or human Bcl-w were generated by transfection with expression vectors for these proteins and selection with hygromycin. Liposome (Lipofectamine, Gibco BRL) mediated transfection of 293T and HeLa cells was performed as previously described. 44 To generate HeLa lines stably overexpressing Bcl-w, cells were transfected with a pEF EE-human Bcl-w PGKhygro vector and were plated at limiting dilution in the presence of 1 mg/ml hygromycin. Clones expressing high levels of Bcl-w were identified by cytoplasmic immunofluorescence staining and flow cytometric analysis. 13 Apoptosis was induced in HeLa cells by UV irradiation (100 J/m 2 ).
Immuno¯uorescence staining and cell sorting
Surface immunofluorescence staining of thymocytes, bone marrow and lymph node cells was performed with cell surface marker-specific monoclonal antibodies as described previously. 4, 45 Antibodies used included RB6-8C5 anti-Gr-1, TER119 anti-erythroid cell-specific surface marker, RA3-6B2 anti-CD45R(B220), GK 1.5 anti-CD4, YTS169 anti-CD8 and M1/70 anti-Mac-1. These antibodies were purified on protein G sepharose and conjugated to FITC, Rphycoerythrin (R-PE), Cy-5 or biotin (Caltag). Viable cells, not stained by propidium iodide (PI, Sigma), were sorted on the basis of cell surface marker expression on a modified FACSII or a FACStar + (Becton Dickinson).
Immunoprecipitation and Western blotting
Primary cells, cell lines or transfected 293T cells were harvested, washed twice in cold PBS and lysed in lysis buffer (20 mM Tris/HCl, pH 8.0, 125 mM NaCl, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 0.5 mg/ml Pefabloc, 1 mg/ml of each of leupeptin, aprotinin, soybean trypsin inhibitor and pepstatin, 5 mM NaF and 2 mM Na 3 VO 4 ; all reagents from Sigma or Roche Diagnostics). For preparation of tissue lysates, organs were excised, washed in PBS, immediately frozen in isopentane on dry ice, and were later homogenized at 48C in lysis buffer as detailed in. 14 Immunoprecipitation was performed according to previously published protocols. 46 Lysates (from 10 7 cells) were pre-cleared by a 2 h incubation at 48C with a control mAb and protein G sepharose before immunoprecipitating with anti-Bcl-w mAbs plus protein G sepharose for 1.5 h. After extensive washing (six times in lysis buffer), the immunoprecipitated material was eluted by boiling in SDS ± PAGE gel loading buffer, size-fractionated on polyacrylamide gels (Novex) and transferred to nitrocellulose membranes (Amersham Pharmacia) by electroblotting. For Western blotting (without prior immunoprecipitation) tissue lysates and lysates of sorted cells were prepared, normalized for total protein content and 30 mg of protein sizefractionated by SDS ± PAGE and electroblotted onto nitrocellulose membranes. Prior to immunoblotting non-specific binding of antibodies to membranes was blocked by incubation overnight in 5% skimmed milk, 1% casein, 0.05% Tween-20. Membranes were then probed with 13F9 or 16H12 anti-Bcl-w mAbs (2 mg/ml) followed by goat anti-rat IgG antibodies conjugated to HRP (Southern Biotechnology) and detection by enhanced chemiluminescence (ECL; Amersham Pharmacia). To control for the concentration and integrity of proteins in the tissue lysates, blots were probed with mouse anti-HSP70 mAb N6 (a gift from Dr R Anderson, Peter MacCallum Cancer Institute, Melbourne, Australia) followed by HRP-conjugated sheep anti-mouse Ig antibodies (Silenus) and detection by ECL.
Subcellular fractionation
HeLa cells were resuspended in HMKEE buffer (20 mM HEPES pH 7.2, 5 mM MgCl 2 , 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 250 mM sucrose buffer and protease inhibitors) and allowed to swell on ice for 10 min at 48C. Cells were lysed using a Dounce homogenizer (100 strokes with a type`B' pestle; Konte Glassware Corporation) or by 50 passages through a 27G needle. 20 After centrifugation at 9006g at 48C for 5 min to pellet nuclei and cell debris, the heavy membrane fraction (HM) was resuspended in HMKEE/sucrose. The resulting supernatant was centrifuged at 100 0006g for 1 h (65 000 r.p.m. for 60 min in a TLA 100.3 Beckman benchtop rotor) to generate the soluble (S) and light membrane (LM) fractions. The pellet was resuspended in RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.5% deoxcholic acid, 50 mM Tris-HCl pH 8.0 plus protease inhibitors). Lysates from equivalent numbers of cells were analyzed by immunoblotting with the rat anti-Bcl-w mAbs 13F11 and 16H12, polyclonal rabbit antiBcl-x antibodies (Pharmingen) and the mouse mAbs antiporin/ VDAC (Calbiochem-Novabiochem Corp), anti-human Bcl-2 (Bcl-2-100) and anti-calnexin (Affinity Bioreagents Inc). Bound antibodies were revealed with HRP-conjugated secondary reagents and ECL detection.
Immuno¯uorescence staining and confocal microscopy
To stain for Bcl-w, HeLa cells stably expressing EE-tagged human Bclw were grown in chamber slides (Becton Dickinson). Cells were attached using Cell Tak (Becton Dickinson), fixed with PBS/4% paraformaldehyde pH 10.0 for 45 min at room temperature 47 and permeabilized with 0.5% Triton X-100. The fixed cells were stained for 1 h at room temp with the primary mAb, mouse anti-EE (Babco), washed with 0.2% Tween-20 in PBS and then incubated with FITCconjugated goat anti-mouse Ig antibodies (Southern Biotechnology). Slides were mounted in fluorescent mounting medium (Dako) containing 100 mg/ml DIABCO (Sigma). Controls included staining with the primary or secondary antibodies alone and staining of parental HeLa cells. To stain for mitochondria, cells were incubated at 378C for 15 min with 500 nM Mito Tracker Red (Molecular Probes). Samples were analyzed with a Leica confocal scanning microscope using SCANware software (Leica Lasertechnik).
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